Jump to navigation Jump to search
Clinical data
ATC code
Pharmacokinetic data
Protein binding96 to 98%
Elimination half-life8-9 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass393.46 g/mol
3D model (JSmol)

WikiDoc Resources for Amsacrine


Most recent articles on Amsacrine

Most cited articles on Amsacrine

Review articles on Amsacrine

Articles on Amsacrine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Amsacrine

Images of Amsacrine

Photos of Amsacrine

Podcasts & MP3s on Amsacrine

Videos on Amsacrine

Evidence Based Medicine

Cochrane Collaboration on Amsacrine

Bandolier on Amsacrine

TRIP on Amsacrine

Clinical Trials

Ongoing Trials on Amsacrine at Clinical

Trial results on Amsacrine

Clinical Trials on Amsacrine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amsacrine

NICE Guidance on Amsacrine


FDA on Amsacrine

CDC on Amsacrine


Books on Amsacrine


Amsacrine in the news

Be alerted to news on Amsacrine

News trends on Amsacrine


Blogs on Amsacrine


Definitions of Amsacrine

Patient Resources / Community

Patient resources on Amsacrine

Discussion groups on Amsacrine

Patient Handouts on Amsacrine

Directions to Hospitals Treating Amsacrine

Risk calculators and risk factors for Amsacrine

Healthcare Provider Resources

Symptoms of Amsacrine

Causes & Risk Factors for Amsacrine

Diagnostic studies for Amsacrine

Treatment of Amsacrine

Continuing Medical Education (CME)

CME Programs on Amsacrine


Amsacrine en Espanol

Amsacrine en Francais


Amsacrine in the Marketplace

Patents on Amsacrine

Experimental / Informatics

List of terms related to Amsacrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Amsacrine (synonyms: m-AMSA, acridinyl anisidide) is an antineoplastic agent.

It has been used in acute lymphoblastic leukemia.[1]


Its planar fused ring system can intercalate into the DNA of tumor cells, thereby altering the major and minor groove proportions. These alterations to DNA structure inhibit both DNA replication and transcription by reducing association between the affected DNA and: DNA polymerase, RNA polymerase and transcription factors.

Amsacrine also expresses topoisomerase inhibitor activity, specifically inhibiting topoisomerase II (compares with the better known agent etoposide).[2] In contrast, the structurally similar o-AMSA differing in the position of the methoxy substituent group on the anilino-ring have little ability to poison topoisomerase II despite of its intercalative behavior, suggesting that intercalation of the molecule in itself is insufficient to trap topoisomerase II as a covalent complex on DNA. [3] [4] [5]


  1. "Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children". Haematologica. 90 (12): 1701–3. December 2005. PMID 16330449.
  2. Genetic Response to Metals. Sarkar, Bibudhendra. CRC Press, 1995. ISBN 978-0-8247-9615-0
  3. "Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: influence of ionic strength and DNA base composition". Nucleic Acids Res. 17 (23): 9933–46. December 1989. doi:10.1093/nar/17.23.9933. PMC 335223. PMID 2602146.
  4. "Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase". Mutagenesis. 2 (5): 349–55. September 1987. doi:10.1093/mutage/2.5.349. PMID 2830452.
  5. "Targeting DNA topoisomerase II in cancer chemotherapy". Nat. Rev. Cancer. 9 (5): 338–50. May 2009. doi:10.1038/nrc2607. PMC 2748742. PMID 19377506.